Skip to main content
. 2021 Jun 8;64(12):8486–8509. doi: 10.1021/acs.jmedchem.1c00420

Figure 7.

Figure 7

HDAC6 is significantly overexpressed in T-PLL patient samples, but not in other T-cell cancers. (a) mRNA expression levels of various HDAC genes (1–6, 9, and 11) in T-cell prolymphocytic leukemia (T-PLL) patient samples, compared to healthy T-cell (CD3+) control samples. Data were extracted from the Oncomine Platform, from the Durig Leukemia data set. HDAC7, 8, and 10 expression levels were not reported in this data set. ns; not significant (p > 0.05). (b) mRNA expression levels of HDAC6 in various T-cell neoplasia patient samples, compared to healthy control cells (from left to right, Eckerle Lymphoma: NK cell, T-cell, NK/T-cell; Piccaluga Lymphoma: CD4+ T-cell, CD8+ T-cell, T-cell; Zhang Leukemia: hematogone, bone marrow; Haferlach Leukemia: peripheral blood mononuclear cells). Data were extracted from the Oncomine Platform, from the Eckerle Lymphoma, Piccaluga Lymphoma, Zhang Leukemia, and Haferlach Leukemia data sets. All comparisons have a p-value > 0.05 and/or a fold-change of ≤1.2 and are not considered significant. Representation: boxes as interquartile range, horizontal line as the mean, and whiskers as lower and upper limits. Abbreviations: ALCL, anaplastic large cell lymphoma; ALK, anaplastic lymphoma kinase; PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; NK, natural killer.